Business
Novavax to deliver 60 mln doses of COVID-19 vaccine candidate to UK for trial – The Jakarta Post – Jakarta Post
US drug developer Novavax Inc said on Friday the UK would buy 60 million doses of its coronavirus vaccine candidate, NVX-CoV2373, for a phase 3 clinical trial in the country.
US drug developer Novavax Inc said on Friday the UK would buy 60 million doses of its coronavirus vaccine candidate, NVX-CoV2373, for a phase 3 clinical trial in the country.
The company and the UK government will collaborate for the trial to assess the efficacy of the vaccine in the UK population, Novavax said in a statement, but did not disclose any financial details of the agreement.
The trial will be a study in about 9,000 adults between 18 years and 85 years of age.
Novavax would partner…
-
Business23 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
Noosa News22 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
General17 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
General22 hours agoOlder Aussies back increased superannuation tax